Publication date: Feb 12, 2020
Objectives: Natalizumab (NTZ), a treatment indicated for patients with highly active Relapsing – Remitting Multiple Sclerosis (RRMS), is known to induce increased relative frequency of lymphocytes. Progressive Multifocal Leukoencephalitis (PML) is a rare but serious adverse event related to NTZ. Moreover, reduced L-selectin (CD62L) expression in T-cells in cryopreserved samples of patients with RRMS under NTZ has been proposed as a biomarker of pre-PML state. We explore the association between L-selectin expression in T-cells and hematological parameters in freshly processed samples of patients with RRMS under NTZ.Methods: We studied L-selectin expression in patients with: RRMS under NTZ (n=34), fingolimod (FTY, n=14), interferon-beta (IFN?, n=22), glatiramer acetate (GA, N=17); in 9 patients with secondary progressive (SP) MS and in 6 healthy controls. Twenty-two patients under NTZ and 6 patients under FTY were followed for 18 months. One NTZ-treated patient developed PML during the study.Results: Patients under NTZ exhibited increased relative frequency of lymphocytes (40.02+/-1.45) compared to patients under first-line treatment (30.57+/-1.68, p
Boziki, M.K., Karapanayotides, T., Papadopoulos, G., Lagoudaki, R., Melo, P., Bakirtzis, C., , Nikolaidis, Gounari, E., , Tsavdaridou, Skoura, L., Afrantou, T., Tatsi, T., Grigoriadou, E., Polyzoidou, E., Mandoras, N., , Giantzi, Kalogera-Fountzila, A., Ioannidis, P., Parissis, D., Pelidou, S.H., Zoidou, S., and Grigoriadis, N. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab – functional implication towards PML risk. 20200. 2020 Neurol Res.
|disease||MESH||progressive Multifocal Leukoencephalopathy|